Ruben Mesa
MD
Executive Director
👥Biography 个人简介
Ruben Mesa has contributed to myelofibrosis clinical research, including contributions to COMFORT-I and COMFORT-II trials establishing ruxolitinib as the first approved therapy for myelofibrosis — demonstrating both reduction in splenomegaly and improved constitutional symptoms and survival. His work on patient-reported outcomes in MPN and on second-generation JAK inhibitors for ruxolitinib-intolerant or resistant myelofibrosis addresses important clinical needs.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ruben Mesa 的研究动态
Follow Ruben Mesa's research updates
留下邮箱，当我们发布与 Ruben Mesa（Mays Cancer Center / UT Health San Antonio）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment